Clinical Trial Update: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating KL-A167 plus cisplatin and gemcitabine versus placebo with cisplatin and gemcitabine for recurrent or metastatic nasopharyngeal carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• KL-A167

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Nasopharyngeal Carcinoma, Recurrent or Metastatic | Phase 3 | Status: ACTIVE_NOT_RECRUITING